Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Lowered to “Hold” at StockNews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

Other analysts have also issued reports about the stock. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $50.73 on Friday. The firm has a fifty day simple moving average of $48.29 and a two-hundred day simple moving average of $43.84. The firm has a market cap of $2.47 billion, a PE ratio of 16.21, a P/E/G ratio of 0.97 and a beta of 0.83. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals has a 1-year low of $36.56 and a 1-year high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The company had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. On average, equities analysts anticipate that Amphastar Pharmaceuticals will post 3.7 EPS for the current year.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Rong Zhou sold 4,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,101 shares of company stock valued at $1,069,350 over the last three months. Corporate insiders own 27.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares during the last quarter. Innealta Capital LLC purchased a new position in Amphastar Pharmaceuticals during the 2nd quarter worth $55,000. Blue Trust Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares in the last quarter. Asset Management One Co. Ltd. acquired a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.